Targeted Therapies for Lung Cancer (eBook)

Artikelnummer: 978-3-030-17832-1
Einband: PDF
Verfügbarkeit: Download, sofort verfügbar (Link per E-Mail)
CHF 153.50
decrease increase

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient's genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors providean in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.


This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient's genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors providean in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.


Schreiben Sie Ihre eigene Bewertung
  • Nur registrierte Benutzer können Produkte bewerten
*
*
Schlecht
Sehr gut
*
*
*
*
VerlagSpringer International Publishing
EinbandPDF
Erscheinungsjahr2019
Seitenangabe238 S.
AusgabekennzeichenEnglisch
AbbildungenIX, 238 p. 19 illus. in color.
Masse4'549 KB
PlattformPDF
ReiheCurrent Cancer Research; Medicine; Medicine
AutorSalgia, Ravi (Hrsg.)

Alle Bände der Reihe "Current Cancer Research; Medicine; Medicine (R0)"

Über den Autor Ravi (Hrsg.) Salgia

Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair in Medical Oncology City of Hope National Medical Center Duarte, California, USA Ravi Salgia, MD, PhD, is Chair of Medical Oncology & Therapeutics Research at City of Hope National Medical Center, in Duarte, California. Dr. Salgia also holds the Arthur and Rosalie Kaplan Chair in Medical Oncology. Previously, Dr. Salgia was Professor of Medicine, Pathology and Dermatology, and the Director of the Thoracic Oncology Program, and Aerodigestive Tract Program Translational Research at the University of Chicago. His research interests focus on novel therapeutics against lung cancer. Dr. Salgia has been honored with numerous awards, including being named one of the Top Doctors in America and awarded the Sun Pharma Distinguished Scientist Award (Clinical Sciences). Prior to his tenure at University of Chicago School of Medicine, Dr. Salgia was faculty at the Dana-Farber Cancer Institute and Harvard Medical School. He earned his undergraduate summa cum laude in mathematics, biology, and chemistry, and then his MD and PhD degrees from Loyola University in Chicago, IL, where he also completed fellowships in neurochemistry and physiology. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins University School of Medicine in Baltimore, MD, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston, MA, during which time he also served as a clinical fellow at Harvard Medical School in Boston. Prakash Kulkarni, Ph.D., is Research Professor and Director of Translational Research in the Department of Medical Oncology and has a courtesy appointment in the Department of Systems Biology at the City of Hope National Medical Centre in Duarte, California. After receiving his PhD in biochemistry from India, he did postdoctoral training in biochemistry at the Indian Institute of Science and in cell biology at the New York University School of Medicine. He was an Assistant Professor at Johns Hopkins University School of Medicine where he was named the Irene and Bernard L. Schwartz Scholar of the Patrick Walsh Fund. He then moved to the W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, as a Research Associate Professor. Prior to joining Johns Hopkins, Prof. Kulkarni held Staff Scientist positions in the Division of Chemistry & Chemical Engineering, the Division of Biology at Caltech, and in the Department of Genetics at Yale University School of Medicine. His research interests are interdisciplinary and are focused on understanding at a system level how conformational dynamics of intrinsically disordered proteins and noise contribute to phenotypic switching, especially in cancer and evolution. Prof. Kulkarni was a Visiting Professor in the Department of Mathematics, and the Department of Bioengineering at the Indian Institute of Science and is currently a Visiting Professor in the Division of Biology and Biological Engineering at Caltech. He is a Fellow of the Royal Society of Biology, UK, and inducted Member, Sigma Xi, The Scientific Research Honor Society.

Weitere Titel von Ravi (Hrsg.) Salgia

Produktbewertungen
Nur registrierte Benutzer können Produkte bewerten